|
Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy. |
| |
|
No Relationships to Disclose |
| |
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
Apostolia Maria Tsimberidou |
Research Funding - Baxter (Inst); Celgene (Inst); EMD Serono (Inst); Foundation Medicine (Inst); NCCN (Inst) |
| |
|
Research Funding - Biomarin; GlaxoSmithKline; Helix BioPharma; Merck; Novartis; Puma Biotechnology |
| |
|
No Relationships to Disclose |
| |
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
| |
|
No Relationships to Disclose |
| |
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Patents, Royalties, Other Intellectual Property - Foundation Medicine |
| |
|
Honoraria - Genentech; Roche; Sysmex |
Consulting or Advisory Role - Genentech; Novartis; Roche |
Research Funding - AstraZeneca; Bayer; Calithera Biosciences; Debiopharm Group; Genentech; Novartis; Taiho Pharmaceutical |
| |
|
No Relationships to Disclose |